Bio

Dr. Steven Tate serves as a Clinical Assistant Professor specializing in addiction medicine within the Department of Psychiatry & Behavioral Sciences at Stanford University School of Medicine. He earned his medical degree from the University of Chicago and completed his internal medicine residency at the University of Pennsylvania. He then successfully completed a fellowship in addiction medicine at Stanford. With a Master's in medical statistics from the London School of Hygiene & Tropical Medicine, Dr. Tate brings a rigorous and evidence-based approach to his work.

Dr. Tate sees patients in the Stanford Dual Diagnosis Clinic, providing comprehensive care for individuals with co-occurring mental health and substance use disorders. He also attends on the inpatient addiction medicine consult service, where he offers guidance to healthcare professionals on complex addiction-related cases. Driven by his dedication to improving care for patients with substance use disorders, he focuses his work on educating future addiction professionals and translating evidence into practice.

Clinical Focus

  • Addiction Medicine
  • Chemical Dependence
  • Tobacco Cessation
  • Opioid Use Disorder
  • Alcohol Withdrawal
  • Behavioral Change
  • Mental Health

Academic Appointments

  • Clinical Assistant Professor, Psychiatry and Behavioral Sciences

Honors & Awards

  • The Steven Lukes Memorial Prize, The University of Chicago Pritzker School of Medicine (2018)
  • Chancellor's Award of Distinction, University of California, Irvine (2012)
  • Laurence J. Mehlman Memorial Scholarship, School of Biological Sciences, University of California, Irvine (2012)

Boards, Advisory Committees, Professional Organizations

  • Member, American College of Academic Addiction Medicine (2021 - Present)
  • Member, American Society of Addiction Medicine (2021 - Present)
  • Member, California Society of Addiction Medicine (2021 - Present)
  • Member, American College of Physicians (2020 - Present)

Professional Education

  • Board Certification, American Board of Preventive Medicine, Addiction Medicine (2023)
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2021)
  • Fellowship, Stanford School of Medicine Department of Psychiatry and Behavioral Sciences, Addiction Medicine (2022)
  • Residency, Hospital of the University of Pennsylvania, Internal Medicine (2021)
  • MD, University of Chicago Pritzker School of Medicine (2018)
  • MSc, London School of Hygiene and Tropical Medicine, Medical Statistics (2017)

Contact

  • Academic
    tates@stanford.edu
    University - Academic staff Department: Psych/General Psychiatry and Psychology (Adult) Position: Clinical Assistant Professor
  • Clinical (Primary)  Psychiatry 401 Quarry Rd Ste 2114 MC 5723 Stanford, CA 94305 (650) 725-3762 (fax)

Additional Clinical Info

Additional Info

All Publications

  • Trends in hallucinogen-associated emergency department visits and hospitalizations in California, USA, from 2016 to 2022. Addiction (Abingdon, England) Garel, N., Tate, S., Nash, K., Lembke, A. 2024

    Abstract

    Hallucinogens encompass a diverse range of compounds of increasing scientific and public interest. Risks associated with hallucinogen use are under-researched and poorly understood. We aimed to compare the trends in hallucinogen-associated health-care use with alcohol- and cannabis-associated health-care use.We conducted an ecological study with publicly available data on International Classification of Diseases, 10th Revision (ICD-10) diagnosis codes associated with emergency department (ED) visits and hospitalizations from the California Department of Healthcare Access and Information (HCAI). HCAI includes primary and secondary ICD-10 codes reported with ED or hospital discharge from every non-federal health-care facility licensed in California, United States, from 2016 to 2022.ICD-10 codes were classified as hallucinogen-, cannabis- or alcohol-associated if they were from the corresponding category in the ICD-10 block 'mental and behavioral disorders due to psychoactive substance use'.Observed hallucinogen-associated ED visits increased by 54% between 2016 and 2022, from 2260 visits to 3476 visits, compared with a 20% decrease in alcohol-associated ED visits and a 15% increase in cannabis-associated ED visits. The observed hallucinogen-associated hospitalizations increased by 55% during the same period, from 2556 to 3965 hospitalizations, compared with a 1% increase in alcohol-associated hospitalizations and a 1% increase in cannabis-associated hospitalizations. This rise in hallucinogenic ED visits was significantly different from the trend in cannabis-associated (P < 0.001) and alcohol-associated (P = 0.005) ED visits. The hallucinogen-associated hospitalizations trend also significantly differed when compared with cannabis- (P < 0.001) and alcohol-associated (P < 0.001) hospitalizations.Hallucinogen-associated emergency department visits and hospitalizations in California, USA, showed a large relative but small absolute increase between 2016 and 2022.

    View details for DOI 10.1111/add.16432

    View details for PubMedID 38213013

  • Generative Artificial Intelligence Tools in Medicine Will Amplify Stigmatizing Language. Journal of addiction medicine Tate, S. 2023

    View details for DOI 10.1097/ADM.0000000000001237

    View details for PubMedID 37862115

  • The ChatGPT therapist will see you now: Navigating generative artificial intelligence's potential in addiction medicine research and patient care. Addiction (Abingdon, England) Tate, S., Fouladvand, S., Chen, J. H., Chen, C. A. 2023

    View details for DOI 10.1111/add.16341

    View details for PubMedID 37735091

https://orcid.org/0000-0001-9544-594X